Make an
impact today
Support our mission by investing in best-in-class technologies.
Sinaptica Therapeutics
-
✽
Clinical Efficacy
A year-long Phase 2 study demonstrated a significant 44%-87% slowdown in cognitive decline for patients with mild-to-moderate Alzheimer’s, achieving statistical significance across all clinical endpoints. This represents a highly effective treatment option, compared to competitors through existing treatments and recently approved monoclonal antibodies with marginal efficacy (26-32%) with burdensome safety concerns
-
✽
Strategic Partnership
An exclusive distribution Letter of Intent (LOI) has been signed with Nexstim, the provider of the hardware stimulation device. This partnership is projected to generate an estimated $6.3 million in the first two years of operations
-
✽
Exceptional Leadership Team
The founding team includes a Director of Noninvasive Brain Stimulation at Saint Lucia Foundation (and Univ. of Ferrara professor) and a Director of Precision Neuroscience at MGH (and Harvard professor). The CEO previously led Boston Scientific’s $1 billion NeuroMod division, with key VPs from Neuronetics (R&D) and Functional Neuromod (Clinical, Phase 3 trials)
-
✽
Strong Intellectual Property
A broad US patent has been granted for TMS-EEG personalization across various diseases, with potential for expansion to other conditions. A diagnostic patent for biomarkers has also been published
-
✽
Regulatory & Commercial Outlook
Regulatory approvals and commercial launches are anticipated to commence in 2029/2030
-
✽
Notable Investors
This funding round is supported by Keiretsu Forum, HealthTech Capital, the CEO of SetPoint Medical, the CEO of NevGen, and a Boston Scientific executive. The existing cap table includes prominent investors such as Sony, Time Zero Capital (Lynk Global), and the Daly family (Time Warner). Note holders include Bootstrap Ventures, Pureland Ventures, and several biotechnology CEOs and other High Networth investors
“Sinaptica’s partnership with Nexstim is a huge step forward”
Abdelkader Yousfi, MBA
“By leveraging the cognitive database, Sinaptica identifies subtle patterns and develops highly targeted treatments, moving us closer to personalized healthcare.”
Oscar Carrasco-Zevallos, PhD
“Sinaptica truly brought us the hope to prevent Alzheimer’s through next-level non-invasive neuromodulation”
Soyoung Park, MBA
“Significant 44%-87% slowdown in cognitive decline for patients with mild-to-moderate Alzheimer’s represents a highly effective treatment option with no major adverse event”
David Crean, PhD, MBA
Make an Investment.
We want to help the aging population to be healthy, productive and independant. We hope we all can maintain our dignity thill the last minute we alive.
Let’s share a healthy future.
Terms of 1004VP’s Investor Syndicate:
A 2% annual management fee for 5 years, which is collected upfront and then drawn down annually over a 10 year period to cover operating expenses and fund admin expenses. Upon a liquidity event in less than 10 years any remaining management fee that has not been drawn down is returned to investors. There is also a 20% carried interest on net profits.
Confidential Information:
All information contained in this page and linked to in this page are confidential and are not to be shared outside of 1004VP's Investor Syndicate investors and LPs in 1004VP Fund I. If you're interested in sharing this opportunity with other accredited investors in your network you must get approval from 1004 Venture Partners before sharing.
$10,000 – Angel Investor
$150,000 – Entity
Custom: $
I agree to a 2% upfront fee (per year for 5 years) to cover SPV setup, legal, admin, compliance, and management expenses. This fee is refundable pro-rata in case of a liquidity event within 5 years.
FAQs
-
A Special Purpose Vehicle (SPV), also known as a Special Purpose Entity (SPE), is a legal entity created for a specific, often temporary purpose. In the context of investment, SPVs are often used to pool capital from multiple investors for a single, focused investment opportunity, such as a startup, real estate venture, or infrastructure project.
How it works
Instead of investors directly owning shares in the target company, they purchase units in the SPV, typically an LLC or LP. The SPV then invests in the company as a single entity, appearing as one line item on the target company's cap table. This simplifies administrative tasks and reduces legal complexity for the company being invested in.
Advantages for investors
Investing through an SPV can offer advantages like lower minimum investment requirements and access to exclusive deals. Other potential benefits include simplified tax reporting through pass-through structures, limited liability, and the ability to invest in specific deals.
Disadvantages for investors
However, disadvantages may include limited diversification, no direct ownership or voting rights in the target company, limited communication with the startup, and various fees that can impact returns.
SPVs offer investors a structured way to access private market investments with lower entry points and streamlined processes. However, investors should be aware of risks such as limited diversification and reliance on the SPV manager. It is recommended to conduct thorough due diligence, understand the fee structure, and consider consulting a financial professional before investing
-
1004VP maintains the SPV Dashboard on the SPV Site. As a 1004VP syndicate investor or a fund LP, you are eligible to access the 1004VP SPV site here.
-
We are building an individual syndicate dashboard. Once your investment is made, you will be able to access the individual dashboard on the SPV site. Stay tuned.
-
A 2% annual fee, along with a 20% carried interest on profits (often called the "2 and 20" structure), is a common fee arrangement in Special Purpose Vehicle (SPV) investments, particularly in venture capital and larger deals.
Here's a breakdown of what that 2% annual fee means in the context of an SPV:
Management Fee: The 2% represents a management fee, which is typically charged annually on the total assets under management (AUM) or committed capital within the SPV.
Purpose: This fee is intended to cover the costs of operating the SPV, including expenses such as salaries, office expenses, professional services (legal, accounting, auditing), and ongoing administration.
Paid by Investors (LPs): The management fee is typically paid by the investors (limited partners or LPs) in the SPV, proportionally to their investment.
One-Time vs. Annual: While the 2% is typically an annual fee, most SPVs may charge a one-time upfront management fee on the committed capital.
Variations: It's important to remember that fee structures can vary. While 2% is a common baseline, some SPVs might charge higher or lower management fees, or even forgo them entirely in favor of alternative arrangements.